NUCB1 and breast cancer: Levels of Nuc-Stat5a were markedly reduced during breast cancer progression, with significant loss of Nuc-Stat5a expression in IDC (P < 0.001) and greatest loss in lymph node metastases (P < 0.001; Figure 1A, C).